Brief: Kazia Therapeutics Announces First Patient Dosed In Phase 1B Trial Of Paxalisib In Advanced Breast Cancer
05/06/2025 13:05
June 5 (Reuters) - Kazia Therapeutics Ltd KZIA.O: KAZIA THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1B TRIAL OF PAXALISIB IN ADVANCED BREAST CANCER Source text: ID:nPn1dXpJsa Further company coverage: KZIA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kazia Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
Kazia drops on $40 mln equity offering to fund breast cancer drug
Kazia slides after breast cancer drug update, equity offering launch
Brief: Kazia Therapeutics Limited Announces Proposed Public Offering